AMC Defense Law's June 2026 'Justice Watch' note read the peptide enforcement signal: compounding pharmacies receiving warning letters and losing licenses, telehealth companies facing criminal indictments, and bulk-substance vendors under federal scrutiny. The FDA has issued more than 50 warning letters to peptide vendors and compounders in 2024-2025, and the agency has signaled an aggressive 503A/503B stance heading into the July 23-24 PCAC meeting that will rule on whether seven peptides return to legal compounding status.
With EASL and ASCO dominating the clinical-data cycle, the FDA peptide-compounding regulatory track continues moving toward the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting. Twelve peptides came off the FDA Category 2 'significant safety risk' bulks list effective April 23, 2026; seven of those (BPC-157, TB-500, KPV, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) advance to the July PCAC for affirmative 503A bulks-list inclusion. A second PCAC before end of February 2027 reviews five more (GHK-Cu injectable, Melanotan II, Cathelicidin LL-37, Dihexa, PEG-MGF). Removal from Category 2 does not yet permit compounding — that requires the affirmative PCAC recommendation plus FDA final determination (6-12 month timeline). The parallel 503B bulks-list proposal excluding semaglutide, tirzepatide, and liraglutide closes public comments June 29. The compounded-semaglutide shipment volume is down 90% year-over-year per the BSR Intelligence briefing as the regulatory vise tightens on the gray-market segment.
The FDA confirmed the Pharmacy Compounding Advisory Committee will convene a second meeting before the end of February 2027 to review five additional peptides for potential 503A Bulk Drug Substances List inclusion: GHK-Cu (injectable formulation specifically — topical/cosmetic remains separate), Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and Mechano Growth Factor Pegylated (PEG-MGF). The February 2027 meeting follows the July 23-24, 2026 PCAC that will review seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2). Compounding pharmacies cannot legally compound these five peptides until the PCAC review concludes and the FDA issues a final determination — a 6-12 month timeline post-meeting. The peptide-specific indications under review span aesthetic dermatology (GHK-Cu, Melanotan II), antimicrobial activity (LL-37), neuroprotection (Dihexa), and growth-factor-mediated tissue regeneration (PEG-MGF).
The Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 — at which seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) will be discussed for 503A compounding inclusion — now has firm public-comment deadlines. Written submissions are due July 9, 2026 via regulations.gov; oral presentation requests close June 30, with the FDA allocating presentation slots after review. The PCAC review follows the April 23, 2026 effective date when 12 peptides came off the FDA's Category 2 bulks list. Industry stakeholders, patient groups, and clinicians are organizing through the SSRPi network and the Alliance for Pharmacy Compounding to coordinate testimony. The combined regulatory cycle — PCAC plus the parallel April 30 503B bulks-list proposal closing June 29 — will reshape the compounding-pharmacy economy through 2027 and determine which research peptides remain accessible through licensed channels.